

# CURRICULUM VITAE

PD Dr. med. Felix Müller

[ORCID](#)

[ResearchGate](#)

[Google Scholar](#)

[kfs.medizin.unibas.ch](#)

Universitäre Psychiatrische Kliniken (UPK) Basel

Wilhelm-Klein-Strasse 27, CH-4012 Basel

Email: felix.mueller@upk.ch

---

## RESEARCH INTERESTS

Acute effects of MDMA, LSD, and psilocybin in humans, neuronal correlates of altered states of consciousness, neurotoxic effects of MDMA, therapeutic effects of LSD and DMT

---

## PROFESSIONAL EXPERIENCE

|                          |                                                                                                                                      |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| <b>05/2024 – present</b> | Co-President of the Swiss Association for Psychedelic-Assisted Therapy (SÄPT)                                                        |
| <b>09/2023 – present</b> | Senior physician, Department of Psychiatry (UPK), Basel                                                                              |
| <b>01/2023 – 06/2023</b> | Senior physician, Division of Clinical Pharmacology and Toxicology, University Hospital Basel                                        |
| <b>09/2020 – 12/2022</b> | Senior physician, Department of Psychiatry (UPK), Basel                                                                              |
| <b>10/2019 – present</b> | Research group leader                                                                                                                |
| <b>04/2013 – 10/2019</b> | Research associate and study physician for several studies investigating the effects of MDMA, LSD, mescaline, and psilocybin         |
| <b>05/2019 - 10/2019</b> | Visiting scholar, Maastricht University, Department of Neuropsychology and Psychopharmacology, University of Maastricht, Netherlands |
| <b>04/2013 - 08/2020</b> | Resident physician, Department of Psychiatry (UPK), Basel                                                                            |

---

## EDUCATION

|                    |                                                                                                                                                                                                                     |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>11/2021</b>     | Habilitation and Venia Docendi (University of Basel)                                                                                                                                                                |
| <b>2018 - 2023</b> | Advanced training in substance-assisted psychotherapy (Swiss Association for Psychedelic-Assisted Therapy)                                                                                                          |
| <b>2014 - 2017</b> | Elementary course in psychoanalysis, Ausbildungszentrum für Psychoanalytische Psychotherapie (AZPP) Basel                                                                                                           |
| <b>2009 - 2012</b> | MD doctoral thesis at the Technical University of Munich (Histopathological evaluation of the toxicity of the alpha-emitter immunoconjugate 213Bi-anti-EGFR-mAb on urinary bladder and kidneys in swiss nu/nu-mice) |
| <b>2006 - 2012</b> | Medical school, Ludwig Maximilians University and Technical University of Munich                                                                                                                                    |
| <b>2002 - 2005</b> | Bakkalaureat in philosophy, logic, and theory of science, Ludwig Maximilians University of Munich and Munich School of Philosophy                                                                                   |
| <b>1997 - 2000</b> | General qualification for university entrance                                                                                                                                                                       |

---

## AWARDS & HONOURS

Swiss Addiction Research Award (SARA) 2019, Inger Salling Award 2020, Prix Frutiger 2022

---

## MEMBERSHIPS

Swiss Association for Psychedelic-Assisted Therapy (SÄPT)

German Society for Psychedelic Research and Therapy (Deutsche Gesellschaft für Psychedelische Forschung und Therapie, DGPFT)

Swiss Society for Psychiatry and Psychotherapy (Schweizerische Gesellschaft für Psychiatrie und Psychotherapie, SGPP)

## APPROVED CLINICAL TRIALS

| Trial                                                                                                                   | ClinicalTrials ID | Role                           |
|-------------------------------------------------------------------------------------------------------------------------|-------------------|--------------------------------|
| Antidepressant response of DMT masked with propofol                                                                     | NCT06927076       | Principal investigator         |
| LSD treatment for persons with alcohol use disorder                                                                     | NCT05474989       | Principal investigator/sponsor |
| The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted                       | NCT05570708       | Principal investigator/sponsor |
| Comparative acute effects of LSD, Psilocybin, and Mescaline                                                             | NCT04227756       | Study physician                |
| Safety and Efficacy of Low Dose MM-120 for ADHD Proof of Concept Trial                                                  | NCT05200936       | Study physician                |
| Psychological, physiological, endocrine, and pharmacokinetic effects of LSD in a controlled study                       | NCT01878942       | Study physician                |
| LSD therapy for persons suffering from major depression                                                                 | NCT03866252       | Principal investigator         |
| Direct comparison of altered states of consciousness induced by LSD and psilocybin                                      | NCT03604744       | Study physician                |
| Role of the serotonin 5HT2A receptor in LSD-induced altered states of consciousness                                     | NCT03321136       | Study physician                |
| Role of dopamine, serotonin and 5HT2A receptors in emotion processing                                                   | NCT03019822       | Study physician                |
| LSD treatment in persons suffering from anxiety symptoms in severe somatic diseases or in psychiatric anxiety disorders | NCT03153579       | Study physician                |
| Neuronal correlates of altered states of consciousness                                                                  | NCT02308969       | Study physician                |
| Effects of methylphenidate, modafinil, and MDMA on emotion-processing in humans: A pharmaco-fMRI study                  | NCT01951508       | Study physician                |

## GRANTS & THIRD-PARTY FUNDING

| Grant                                                                                                                                                                                                                                   | Year | Amount (CHF)     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|------------------|
| INTEGRATE - Interdisciplinary Network for Training, Education, and Growing Research into Applications of and Therapeutic Expertise around Psychedelics. Horizon Europe Marie Skłodowska-Curie Networks                                  | 2025 | 361 609          |
| Swiss National Science Foundation (SNF): Investigating the role of the psychedelic experience in the antidepressant response in patients with major depression: a placebo-controlled factorial trial with DMT masked with propofol      | 2024 | 431 520          |
| Swiss National Science Foundation (SNF): Investigating efficacy and microstructural plasticity of LSD treatment in patients with alcohol use disorder                                                                                   | 2024 | 735 114          |
| ANIVA Foundation: The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training                                                                                                    | 2023 | 670 000          |
| Gertrud-Thalmann-Fonds: LSD therapy for persons suffering from major depression: a randomised, double-blind, active-placebo controlled phase II study                                                                                   | 2021 | 30 000           |
| Forschungsförderungsfond der Universitären Psychiatrischen Kliniken (co-applicant): LSD-assisted treatment for persons suffering from alcohol dependence: A multi-centered, randomized, double-blind, placebo-controlled phase II study | 2021 | 20 000           |
| Swiss National Science Foundation (SNF Scientific Exchanges; IZSEZO_186351): Psilocybin as a tool for enhanced divergent thinking and positive learning mechanisms                                                                      | 2019 | 18 500           |
| Gertrud-Thalmann-Fonds: LSD therapy for persons suffering from major depression: a randomised, double-blind, active-placebo controlled phase II study                                                                                   | 2018 | 120 000          |
| Forschungsförderungsfond der Universitären Psychiatrischen Kliniken: Neuronal correlates of altered states of consciousness                                                                                                             | 2016 | 27 000           |
| Forschungsförderungsfond der Universitären Psychiatrischen Kliniken: Neuronal correlates of altered states of consciousness                                                                                                             | 2015 | 31 000           |
| <b>Total third-party funding</b>                                                                                                                                                                                                        |      | <b>2 444 743</b> |

## SUPERVISION OF JUNIOR RESEARCHERS

---

PhD thesis Charlotte Schiewe: The Impact of Controlled Self-Experience with Psychedelics in Therapist Training

PhD thesis Anna Boeker: Evidence-Based Implementation of Psychedelic-Assisted Therapy

Master thesis, Valentin Basil Rohr: *Participant Perspectives on Group Setting Aspects in Ayahuasca-Inspired Interventions: A Qualitative Study* (second advisor)

PhD thesis Laura Ley: *Pharmacology, physiology, and psychology of serotonergic psychedelics in healthy participants* (second adviser)

MD doctoral thesis Philip Hinüber: One-year follow-up of the effectiveness of LSD-assisted therapy for the treatment of major depression: A randomized clinical trial

MD doctoral thesis Dennis Knuchel: *A randomized trial on low- versus high-dose LSD-assisted therapy in patients with major depression: Effects on psychopathology, inflammatory markers, sleep, and daily activity.*

MD doctoral thesis, Nicole Geiger: *A one-year follow-up of a randomized trial on LSD for the treatment of major depression*

Master thesis, Luisa Schertenleib: *Qualitative analysis of patient experiences in a study on LSD for major depression*

MD doctoral thesis, Hannes Zaczek: *Qualitative analysis of patient experiences in a study on LSD for major depression*

MD doctoral thesis, Elias Kraus: *Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants*

Master thesis, Alain Solterman: *The dreamlike state of psychedelics: Phenomenological and neurophysiological investigations with LSD*

MD doctoral thesis, Raphael Brändle: *Neuroimaging in MDMA use: A meta-analysis of the literature*

## OTHER ACTIVITIES

---

Member of the Evaluation Group "Revision of the Narcotics Act" of the Federal Office of Public Health (FOPH)

Chair data safety monitoring committee Zenon Therapeutics

Co-Chair Symposium: Jenseits von Psilocybin bei Depression – weitere mögliche Anwendungsgebiete für substanzgestützte Therapien. DGPPN Congress, Berlin (11/2023)

Co-Chair Symposium: Auf dem Weg zu einem evidenzbasierten Einsatz von Psychedelika in der Psychiatrie. DGPPN Congress, Berlin (11/2022)

Guest associate editor *Frontiers in Psychiatry* for the special issue *Hallucinogens and entactogens: Establishing a new class of psychotherapeutic drugs?* and *Hallucinogens and entactogens: Establishing a new class of psychotherapeutic drugs? Volume II*

## PUBLICATIONS

---

### Peer-reviewed articles

| No. | Publication                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1   | Breeksema, J.J., Bremberg, U., van Dalen, J.H., Lindskog, M., Páleníček, T., Stenbæk, D.S., Granqvist, P., Dalla, C., Antoniou, K., <b>Müller, F.</b> , Aicher, H.D., Dupuis, D., Seybert, C., Oliveira-Maia, A.J., Scheidegger, M., van Elk, M., Sampaio, F., Feldman, I., Hallgreen, C.E., Brun, N.C., Toebes, B., Friedel, E., Repantis, D., Schoevers, R.A. 2026. <i>T-shaped expertise. Rethinking interdisciplinarity in psychedelic research.</i> Psychedelics. |
| 2   | Avram, M., Menegaux, A., <b>Müller, F.</b> , Zaczek, H., Korda, A., Rogg, H., Becker, A.M., Ley, L., Liechti, M.E., Borgwardt, S. 2026. <i>Neuroplastic White Matter Changes in Patients with Major Depression Following Lysergic Acid Diethylamide Treatment.</i> Cell Reports Medicine.                                                                                                                                                                              |
| 3   | Meyer, M., Mosandl, C.F., Guessoum, A., Herrmann, O., Baltes-Flückiger, L., Pichler, E.M., Zadic, A., Maleska Maceski, A., Vilchez Gomez, J.F., Dürsteler, K.M., <b>Müller, F.</b> , Lang, U.E., Benkert, P., Kuhle, J., Walter, M., Vogel, M. 2026. <i>NfL and GFAP quantification and associations with mental health in recreational cannabis users – Results from the Swiss study on recreational cannabis access via pharmacies.</i> Molecular Neurobiology.      |

- 4 Florineth, G.A., Klima, I., Boeker, A.L., Catzeflis, P., Wopfner, A., Denier, N., Bracht, T., Adorjan, K., Pfammatter, M., **Müller, F.**, Soravia, L.M. 2025. *Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy. A Systematic Review and Meta-Analysis.* JAMA Network Open.
- 5 Girn, M., Doss, M.K., Roseman, L., Preller, K.H., Palhano-Fontes, F., Pasquini, L., Barrett, F.S., Mallaroni, P., Mason, N.L., Timmermann, C., McCulloch, D.E., Fisher, P.M., Winston, B.S., Moujaes, F., **Müller, F.**, Liechti, M.E., Vollenweider, F.X., Ramaekers, J.G., Kuypers, K., Araujo, D.B., Sporns, O., Siegel, J., Dosenbach, N., Nutt, D.J., Carhart-Harris, R.L., Stamatakis, E.A., Bzdok, D. *An international mega-analysis of psychedelic drug effects on brain circuit function.* Nature Medicine.
- 6 Liechti, M.E., Gasser, P., Aicher, H.D., **Müller, F.**, Hawrot, T., Schmid, Y. 2025. Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program. *Neuroscience Applied.*
- 7 **Müller, F.**, Zaczek, H., Becker, A. M., Ley, L., Borgwardt, S., Santos de Jesus, J., Loh, N., Kohut, J., Auernig, M., Boehlke, C., Liechti, M. E. 2025. *Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial.* Med.
- 8 Mueller, L., Santos de Jesus, J., Schmid, Y., **Müller, F.**, Becker, A., Klaiber, A., Straumann, I., Luethi, D., Haijen, E., Hurks, P., Kuypers, K., Liechti, M. 2025. *Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial.* JAMA Psychiatry.
- 9 Kraus, E., Suter, S., Proescholdt, M. **Müller, F.**, Liechti, M.E., Heim, M., Lang, U.E., Vogel, M. 2025. *Case Report: Well-tolerated MDMA-assisted therapy in a 32-year old female patient with advanced alcohol-induced liver cirrhosis.* Psychiatry Research Case Reports.
- 10 Aicher, H., **Müller, F.**, Gasser, P. 2025. Further Education in Psychedelic-Assisted Therapy – Experiences from Switzerland. BMC Medical Education.
- 11 **Müller, F.**, Sauer, T., Hännly, C., Mühlhauser, M., Lang, U.E. 2025. Suicide of a patient shortly after psilocybin-assisted psychedelic therapy: A case report. *Psychiatry Research.*
- 12 Avram, M., Fortea, L., Wollner, L., Coenen, R., Korda, A., Rogg, H., Holze, F., Vizeli, P., Ley, L., Radua, J., **Müller, F.**, Liechti, M., Borgwardt, S. 2024. *Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxymphetamine.* Molecular Psychiatry.
- 13 Vizeli, P., Studerus, E., Holze, F., Schmid, Y., Dolder, P., Ley, L., Straumann, I., Becker, A., **Müller, F.**, Arikci, D., Liechti, M. 2024. *Pharmacological and Non-Pharmacological Predictors of the LSD Experience in Healthy Participants.* Translational Psychiatry.
- 14 Holze, F., Gasser, P., **Müller, F.**, Strebel, M., Liechti, M.E. 2024. *LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up.* Br J Psychiatry.
- 15 Bedford, B., Hauke, D., Wang, Z., Roth, V., Nagy-Huber, M., Holze F., Ley, L., Vizeli, P., Liechti, M.E., Borgwardt, S., **Müller, F.** & Diaconescu, A. 2023. The effect of lysergic acid diethylamide (LSD) on whole-brain functional and effective connectivity. *Neuropsychopharmacology.* (Shared last authorship).
- 16 Rogg, H., Avram, M., **Müller, F.**, Zimmermann, C., Junghanns, K., Borgwardt, S. & Zurovski, B. Z. 2022. Ketamine as a treatment option for severe Borderline Personality Disorder: A Case Report. *The Journal of Clinical Psychopharmacology.*
- 17 Holze, F., Gasser, P., **Müller, F.**, Dolder, P. C. & Liechti, M. E. 2022. Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness A randomized, double-blind, placebo-controlled Phase II study. *Biological Psychiatry.*
- 18 McCulloch, D. E. W., Knudsen, G. M., Barrett, F. S., Doss, M. K., Carhart-Harris, R. L., Rosas, F. E., Deco, G., Kringelbach, M. L., Preller, K. H., Ramaekers, J. G., Mason, N. L., **Müller, F.** & Fisher, P. M. 2022. Psychedelic Resting-state Neuroimaging: A Review and Perspective on Balancing Replication and Novel Analyses. *Neuroscience & Biobehavioral Reviews.*
- 19 Avram, M., **Müller, F.**, Rogg, H., Korda, A., Andreou, C., Holze, F., Vizeli, P., Ley, L., Liechti, M. E. & Borgwardt, S. 2022. Characterizing thalamocortical (dys)connectivity following d-amphetamine, LSD, and MDMA administration. *Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.*
- 20 Holze, F., Ley, L., **Müller, F.**, Becker, A. M., Straumann, I., Vizeli, P., Kuehne, S. S., Roder, M. A., Duthaler, U., Kolaczynska, K. E., Varghese, N., Eckert, A. & Liechti, M. E. 2022. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. *Neuropsychopharmacology.*
- 21 Avram, M., Rogg, H., Korda, A., Andreou, C., **Müller, F.**, Borgwardt, S., 2021. Bridging the Gap? Altered Thalamocortical Connectivity in Psychotic and Psychedelic States. *Frontiers in Psychiatry.*
- 22 **Müller, F.**, Kraus, E., Holze, F., Becker, A., Ley, L., Schmid, Y., Vizeli P., Liechti, M.E., Borgwardt, S., 2022. Flashback phenomena after administration of LSD and psilocybin in controlled studies with healthy participants. *Psychopharmacology.*

- 23 Mason, N.L., Kuypers, K.P.C., Reckweg, J.T., **Müller, F.**, Tse, D.H.Y., da Rios, B., Toennes, S.W., Stiers, P., Fielding, A., Ramaekers, J.G., 2021. Spontaneous and deliberate creative cognition during and after psilocybin exposure. *Transl. Psychiatry*.
- 24 Holze, F., Vizeli, P., Ley, L., **Müller, F.**, Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., Liechti, M.E., 2021. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. *Neuropsychopharmacology*.
- 25 **Müller, F.**, Holze, F., Dolder, P., Ley, L., Vizeli, P., Soltermann, A., Liechti, M.E., Borgwardt, S., 2021. MDMA-induced changes in within-network connectivity contradict the specificity of these alterations for the effects of serotonergic hallucinogens. *Neuropsychopharmacology*.
- 26 **Müller, F.**, Mühlhauser, M., Holze, F., Lang, U.E., Walter, M., Liechti, M.E., Borgwardt, S., 2020. Treatment of a Complex Personality Disorder Using Repeated Doses of LSD—A Case Report on Significant Improvements in the Absence of Acute Drug Effects. *Front. Psychiatry*.
- 27 **Müller, F.**, Johnson, M.W., Borgwardt, S. 2020. Editorial: Hallucinogens and entactogens: Establishing a new class of psychotherapeutic drugs? *Frontiers in Psychiatry*.
- 28 Mason, N, Kuypers, K., **Müller, F.**, Reckweg, J., Tse, D., Toennes, S., Hutten, N., Jansen, J., Stiers, P., Fielding, A., Ramaekers, J.G. 2020. Me, Myself, Bye: Regional alterations in glutamate and the experience of ego dissolution with psilocybin. *Neuropsychopharmacology*.
- 29 Holze, F., Vizeli, P., **Müller, F.**, Ley, L., Duerig, R., Varghese, N., Eckert, A., Borgwardt, S., Liechti, M.E. 2019. Distinct acute effects of LSD, MDMA, and D-amphetamine in healthy subjects. *Neuropsychopharmacology*.
- 30 **Müller, F.**, Borgwardt, S. 2019 Acute effects of lysergic acid diethylamide (LSD) on resting brain function. *Swiss Med Wkly*.
- 31 Holze, F., Duthaler, U., Vizeli, P., **Müller, F.**, Borgwardt, S., Liechti, M. 2019. Pharmacokinetics and subjective effects of a novel oral LSD formulation in healthy subjects. *Br J Clin Pharmacol*.
- 32 **Müller, F.**, Brändle, R., Liechti, M.E., & Borgwardt. 2018. Neuroimaging of chronic MDMA („ecstasy“) effects: A meta-analysis of the literature. *Neurosci Biobehav Rev*.
- 33 **Müller, F.**, Liechti, M.E., Lang, U.E., & Borgwardt, S. 2018. Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain. *Progress in Brain Research*.
- 34 **Müller, F.**, Dolder, P. C., Schmidt, A., Liechti, M. E. & Borgwardt, S. 2018. Altered network hub connectivity after acute LSD administration. *NeuroImage: Clinical*.
- 35 Schmidt, A., **Müller, F.**, Dolder, P. C., Schmid, Y., Zanchi, D., Egloff, L., Liechti, M. E. & Borgwardt, S. 2017. Acute effects of methylphenidate, modafinil and MDMA on negative emotion processing. *Int J Neuropsychopharmacol*.
- 36 Schmidt, A., **Müller, F.**, Lenz, C., Dolder, P. C., Schmid, Y., Zanchi, D., Lang, U. E., Liechti, M. E. & Borgwardt, S. 2017. Acute LSD effects on response inhibition neural networks. *Psychol Med*.
- 37 **Müller, F.**, Lenz, C., Dolder, P. C., Lang, U. E., Schmidt, A., Liechti, M. E. & Borgwardt, S. 2017. Increased thalamic resting state connectivity as a core driver of LSD-induced hallucinations. *Acta Psychiatrica Scandinavica*.
- 38 Dolder, P. C., Grunblatt, E., **Müller, F.**, Borgwardt, S. J. & Liechti, M. E. 2017. A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects. *Front Pharmacol*.
- 39 Dolder, P. C., **Müller, F.**, Schmid, Y., Borgwardt, S. J. & Liechti, M. E. 2017. Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. *Psychopharmacology (Berl)*.
- 40 Schmidt, A., **Müller, F.**, Dolder, P. C., Schmid, Y., Zanchi, D., Liechti, M. E. & Borgwardt, S. 2017. Comparative effects of methylphenidate, modafinil and MDMA on response inhibition neural networks in healthy subjects. *Int J Neuropsychopharmacol*.
- 41 **Müller, F.**, Lenz, C., Dolder, P. C., Harder, S., Schmid, Y., Lang, U. E., Liechti, M. E. & Borgwardt, S. 2017. Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects. *Transl Psychiatry*.
- 42 Dolder, P. C., Schmid, Y., **Müller, F.**, Borgwardt, S. & Liechti, M. E. 2016. LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality. *Neuropsychopharmacology*.
- 43 **Müller, F.**, Lenz, C., Steiner, M., Dolder, P. C., Walter, M., Lang, U. E., Liechti, M. E. & Borgwardt, S. 2015. Neuroimaging in moderate MDMA use: A systematic review. *Neurosci Biobehav Rev*.
- 44 Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., **Müller, F.**, Borgwardt, S. & Liechti, M. E. 2015. Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects. *Biol Psychiatry*.



## Book chapters & other publications

### No. Publication

- 45 Strickler, E., Prinz, S., Müller, F., Aicher, H.D. 2026. Psychedelika-assistierte Therapie: Überblick und Entwicklungen in der Schweiz. Psychiatrische Pflege.
- 46 Soravia, L.M., Bracht, T., Denier, N., Schmid, Y., Müller, F. 2026. Hallucinogens. In: Adorjan, K., Schulze, T.G., Walsh, S.L. (eds.), *New Psychoactive Substances*. Oxford University Press
- 47 Aicher, H. & Müller, F. 2025. Erfahrungen mit der beschränkten medizinischen Anwendung von Psychedelika in der Schweiz. *Schweizer Zeitschrift für Psychiatrie+Neurologie*.
- 48 Holze, F., Liechti, M.E., Müller, F. 2024. *Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms*. *Curr Top Behav Neurosci*.
- 49 Kraehenmann, R., Bachmann-Heinzer, R., Bruehl, A., Haettenschwiler, J., Hasler, G., Herdener, M., Herwig, U., Hubl, D., Kemter, A., Müller, F., Obrich, S., Rota, F., Vogel, M., Walther, S., Seifritz, E. 2024. *Schweizer Behandlungsempfehlungen Psychedelika-Therapie*. Schweizerische Ärztezeitung.
- 50 Aicher, H., Duffour, C., Liechti, M.E., Zullino, D., Angerbauber, M., Binswanger, J., Brand, M., Calame, A., Claus, M., Hasler, G., Hein, O., Herwig, U., Liaudat, V., Müller, F., Scelle, CH., Schmid, Y., Styk, J., Thoren, G., Weigle, C., Wopfner, A., Gasser, P. 2024. Treatment Recommendations for Psychedelic-assisted Therapy. *Swiss Archives of Neurology, Psychiatry and Psychotherapy*.
- 51 Krähenmann, R., Seifritz, E., Brühl, A., Gasser, P., Hasler, G., Herdener, M., Kemter, A., Müller, F., Olbrich, S., Styk, J., Thorens, G., Vogel, M., Walther, S. 2023. Positionspapier: Medizinische Behandlungen mit Psychedelika. *Schweizerische Ärztezeitung*.
- 52 Avram, M., Müller, F., & Borgwardt, S. 2023. Lysergic acid diethylamide: In search for the wonder drug. In D. Nutt & D. Castle (Eds.), *Psychedelics As Psychiatric Medications*. Oxford Psychiatry Library.
- 53 Müller, F. 2023. LSD als Therapeutikum in der Psychiatrie? Ärzte Zeitung.
- 54 Müller, F. 2022. Behandlung der Alkoholabhängigkeit mit halluzinogenen Substanzen. *Schweizer Zeitschrift für Psychiatrie & Neurologie*.

## ORAL PRESENTATIONS

### Conference presentations

- 2026** *Risiken und Nebenwirkungen der Therapie mit Psychedelika*. Deutscher Psychotherapie Kongress. Berlin (06/2026)  
*Programm und Erfahrungen mit der beschränkten medizinischen Anwendung von Psychedelika in der Schweiz*. Workshop Wie sollte sich Deutschland auf die psychedelische Renaissance vorbereiten? Interdisziplinäre Perspektiven. Berlin (03/2026)
- 2025** *Psychedelika-gestützte Therapie von Abhängigkeitserkrankungen*. Fachtagung der Deutschen Gesellschaft für Suchtpsychologie (DGSPS). Köln (10/2025)
- 2024** *Halluzinogene in der Behandlung von psychischen Erkrankungen – Aktuelle Entwicklungen*. Symposium Addiction Psychology Switzerland - Psychedelika in der Psychotherapie von Substanzkonsumstörungen (08/2024)
- 2023** *Halluzinogene in der Behandlung von psychischen Erkrankungen – Aktuelle Entwicklungen*. 11. Fachtagung Integrierte Psychiatrie im Diskurs, Winterthur (03/2023)  
*LSD in der Behandlung von Menschen mit depressiven Erkrankungen*. Conference „LSD 80“, Münchenstein (04/2023)  
*LSD bei depressiven Erkrankungen – eine randomisiert-kontrollierte Phase II-Studie*. DGGPN Kongress Berlin (11/2023)
- 2022** *Pilze statt Pillen? Halluzinogene in der Behandlung von Abhängigkeitserkrankungen*. Nordwestschweizer Suchtsymposium (03/2022)  
*LSD – Phase-I und Studien bei Angststörungen und Depression*. DGGPN Kongress Berlin (11/2022)
- 2019** *Altered network hub connectivity after acute LSD administration – fMRI studies on the neuronal effects of LSD*. Dutch Neuroscience Meeting (6/2019)  
*Research on the subjective and neuronal effects of LSD*. Swiss Addiction Research Day (9/2019)
- 2018** *LSD treatment in persons suffering from anxiety symptoms in severe somatic diseases or in psychiatric anxiety disorders*. SGPP Jahreskongress (9/2018)
- 2017** *Aktuelle Humanforschung mit LSD*. SGPP Jahreskongress, Bern (9/2017)

## **Professional training**

- 2026**     *Psychedelika-assistierte Therapie in der Schweiz.* Sanatorium Kilchberg (02/2026)  
*Fallbericht: Suizid eines Patienten nach Psilocybin-assistierter Therapie.* Arbeitsgemeinschaft „PAT in den Institutionen“. Klinik Südhang, Kirchlintach (03/2026)  
*Halluzinogene in der Behandlung von psychischen Erkrankungen – Aktuelle Entwicklungen.* Klinik Barmelweid (05/2026)  
*Pilze statt Pillen? Psychedelika in der Behandlung psychischer Erkrankungen.* Recordati Webinar Plus (06/2026)  
*Psychedelika in der Behandlung von Abhängigkeitserkrankungen.* Psychiatrie Baselland (07/2026)
- 2025**     *Können Drogen nützlich sein? LSD, Psilocybin und MDMA in der Psychotherapie.* Akzept-Fachtag Drogenhilfe – Die Zukunft ist jetzt. Münster (01/2025)  
*Psychedelics in the treatment of mental disorders – Current developments and situation in Switzerland.* Clinica psichiatrica cantonale, Mendrisio (03/2025)  
*Halluzinogene in der Behandlung von psychischen Erkrankungen – Aktuelle Entwicklungen.* Psychiatrie Plus. Küssnacht (05/2025)  
*Halluzinogene in der Behandlung von psychischen Erkrankungen – Aktuelle Entwicklungen.* Montagskolloquium. Universitäre Psychiatrische Kliniken Basel (05/2025)  
*Psychedelische Therapie.* Psychiatrie Update Refresher - Forum für medizinische Fortbildung. Zürich (05/2025)  
*Klinische Studien mit LSD, Psilocybin und MDMA.* Tagung „Psychedelika in der Psychiatrie“. Zentrum für Psychiatrie Reichenau (05/2025)  
*Halluzinogene in der Behandlung von psychischen Erkrankungen – Aktuelle Entwicklungen.* Psychiatrie Plus. Bad Horn (06/2025)  
*Halluzinogene in der Behandlung von psychischen Erkrankungen – Aktuelle Entwicklungen.* Psychiatriezentrum Clenia Wetzikon (09/2025)  
*Nebenwirkungen und schwierige Erfahrungen bei Psychedelika und MDMA.* Weiterbildung der Schweizerischen Ärztesgesellschaft für Psycholytische Therapie. Basel. (09/2025)  
*Aktueller Stand der Psychedelika-Forschung – Evidenzbasierte Medizin.* Weiterbildung der Schweizerischen Ärztesgesellschaft für Psycholytische Therapie. Basel. (09/2025)  
*Psychedelics in the treatment of mental disorders.* Herbstkongress der Schweizerischen Gesellschaft für Allgemeine Innere Medizin. St. Gallen (09/2025)  
*Psychedelische Therapie.* Psychiatrie Update Refresher - Forum für medizinische Fortbildung. Zürich (11/2025)  
*Psychedelika in der Behandlung psychischer Erkrankungen.* Lecture as part of the elective course 'Translational Psychology' at the University of Basel (11/2025)  
*Psychedelics in the treatment of mental disorders.* Professional training of the Swiss Society for Interventional Psychiatry (SGIP) (12/2025)
- 2024**     *Halluzinogene in der Behandlung von psychischen Erkrankungen – Aktuelle Entwicklungen.* Helsana Health Insurance (05/2024)  
*Clinical application of LSD, psilocybin, and MDMA – My lessons learned.* Workshop The Renaissance of Psychedelic Therapies: Lessons from Switzerland. Brocher Foundation (06/2024)  
*Halluzinogene in der Behandlung von psychischen Erkrankungen – Aktuelle Entwicklungen.* Forum Suchtmedizin Ostschweiz (10/2024)
- 2023**     *LSD als Therapeutikum in der Psychiatrie – Standortbestimmung und Ausblick.* Forum Sucht und Drogen, Zürich (08/2023)  
*Halluzinogene Wirkstoffe in der Psychiatrie - Standortbestimmung und Ausblick.* Klinik für Psychiatrie und Psychotherapie, Bamberg (09/2023)  
*Halluzinogene in der Behandlung von psychischen Erkrankungen – Aktuelle Entwicklungen.* Forum Suchtmedizin Ostschweiz (11/2023)
- 2022**     *Pilze statt Pillen? Halluzinogene in der Behandlung von Abhängigkeitserkrankungen.* Klinik Südhang, Kirchlintach (05/2022)

- Pilze statt Pillen? Die Renaissance der Halluzinogene in der Psychiatrie.* Weiterbildung Psychiatrische Dienste Solothurn (07/2022)
- 2021** *Pilze statt Pillen? Die Renaissance der Halluzinogene in der Psychiatrie.* Universitätsklinikum Schleswig-Holstein, Campus Lübeck (01/2021)
- International Association of Forensic Toxicologists (TIAFT) Education Symposium (07/2021)
- 2020** *Pilze statt Pillen? Die Renaissance der Halluzinogene in der Psychiatrie.* Klinik für Forensik. Universitäre Psychiatrische Kliniken Basel (11/2020)
- 2019** *Pilze statt Pillen? Die Renaissance der Halluzinogene in der Psychiatrie.* Klinikum rechts der Isar, Technical University Munich (3/2019)
- Pilze statt Pillen? Die Renaissance der Halluzinogene in der Psychiatrie.* Isar-Amper-Klinikum Munich (10/2019)

#### Public lectures

- 2026** Psychedelika-Therapie: Stand der Forschung und Anwendung in der Schweiz. Magic Bus Evolution, Bern (04/2026)
- 2025** *Klinische Studien mit LSD, Psilocybin und MDMA.* Psychedelic Awareness & Research Association (PARAB), Universität Basel (11/2025)
- 2024** Halluzinogene in der Behandlung von psychischen Erkrankungen. Historisches Museum Basel (05/2024)
- 2023** *Halluzinogene zur Behandlung von psychischen Erkrankungen.* Woche des Gehirns, Universität Basel (03/2023)
- 2016** *Acute effects of LSD on amygdala activity during emotional processing in healthy humans.* Tag der Klinischen Forschung, Universitätsspital Basel (1/2016)

#### PUBLIC OUTREACH

---

- 2026** *Gegen Alkoholsucht: Basel und Bern nehmen LSD, Zürcher testen Ketamin.* 20 min (03/2026)
- Les psychédéliques peuvent déclencher des épisodes psychotiques.* 20 heures (06/2026)
- 2025** *Heilsam oder gefährlich – LSD in der Therapie.* Radio Bern Rabe (02/2025)
- Heilung und Selbsterkenntnis durch psychoaktive Substanzen.* natürlich (03/2025)
- EKT, LSD und Mikrobiom – Historische Therapien revisited.* Podiumsdiskussion Historisches Museum Basel (03/2025)
- Halluzinationen vom Arzt verschrieben.* Bz Schweiz am Wochenende (04/2025)
- Warum LSD gerade ein Revival in der Psychotherapie erlebt.* Basel jetzt (04/2025)
- Wie eine Schweizer Klinik Alkoholranke mit Magic Mushrooms heilen will.* NZZ (07/2025)
- Microdosing: Was steckt hinter dem Trend?* Welt-Podcast «Aha! Zehn Minuten Alltags-Wissen» (09/2025)
- Wenn Drogen zu Medizin werden.* Ursache/Wirkung (08/2025)
- Drogen in der Psychotherapie.* SRF News Video (11/2025)
- Trip auf Rezept.* Business Punk (11/2025)
- “Psychedelika kommen der Wurzel näher”.* Chrismon (12/2025)
- 2024** *LSD hilft gegen Depression und Angststörungen.* SWR 2 (02/2024)
- Was es mit dem Microdosing von LSD auf sich hat.* Apotheken Umschau (02/2024)
- Wie gefährlich ist der Trend zur Einnahme kleiner Mengen LSD?* Die Welt (03/2024)
- Sind Mini-Mengen LSD wirklich ungefährlich?* ntv (03/2024)
- Therapien mit Zauberpilzen und LSD nehmen rasant zu.* Tagesanzeiger, Der Bund, BAZ, Berner Zeitung (07/2024)
- Jenke. Experiment. Alltagsdrogen. Besser, schneller, schlauer – wie gedopt ist Deutschland?* Pro 7 (10/2024)
- Was ich im LSD-Retreat erlebt habe.* Süddeutsche Zeitung und Tagesanzeiger (11/2024)
- 2023** Podcast broad.cats (02/2023)
- LSD bei Depression.* SRF Gesundheit heute (02/2023)
- LSD könnte Symptome einer Depression lindern.* Schweizer Familie (02/2023)



- Studie zeigt positive Wirkung von LSD bei Depressionen. Der Spiegel, Die Zeit, Süddeutsche Zeitung, Tagesanzeiger (04/2023)*
- LSD zeigt Wirkung gegen Depressionen. FAZ (04/2023)*
- Studie zeigt positive Wirkung von LSD bei Depressionen. BAZ (04/2023)*
- 80 Jahre LSD: Vom Medikament zur Droge - und zurück? Frankfurter Rundschau (04/2023)*
- Vom Arzneimittel zur Droge zum Arzneimittel. Pharmazeutische Zeitung (04/2023)*
- Horror Droge oder ein Wundermittel? LSD könnte Depressionen lindern. Tagesspiegel (04/2023)*
- Studie zeigt positive Wirkung von LSD bei Depressionen. Die Welt (04/2023)*
- LSD als Medikament. Podcast Unisonar (09/2023)*
- 2022** *Microdosing: Können LSD & Co die Leistung steigern?. Pro 7 Wissenssendung Galileo (02/2022)*
- Your brain on psychedelics. Nature (09/2022)*
- Hilft LSD gegen Depression? Radio X (10/2022)*
- Ist LSD das verbotene Wundermittel gegen Depressionen? Krautreporter (12/2022)*
- LSD-unterstützte Psychotherapie lindert Ängste. Springer Medizin (12/2022)*
- „Wie das Glücksserum bei Harry Potter“ Kreativ und konzentriert? Warum Menschen LSD mikrodosieren. Tagesspiegel (12/2022)*
- 2018** *Talk:: „...zur seelischen Auflockerung bei analytischer Psychotherapie“ – Halluzinogene Drogen in der Psychiatrie. Science and Fiction. Basel (05/2018)*
- 2017** *Potenzial für die Psychotherapie. TagesWoche (04/2017)*
- LSD dämpft Angstgefühle. Neue Zürcher Zeitung (04/2017)*
- LSD dämpft Angstempfinden. Österreichischer Rundfunk (04/2017)*